Related Experiment Videos
DDAVP reduces bleeding during continued hirudin administration in the rabbit
C M Bove1, B Casey, V J Marder
1Department of Medicine, University of Rochester School of Medicine & Dentistry, New York 14642, USA.
Thrombosis and Haemostasis
|March 1, 1996
Summary
Desmopressin (DDAVP) infusion significantly reduced bleeding time in rabbits treated with the anticoagulant hirudin. This suggests DDAVP may mitigate hirudin-induced hemorrhage, supporting clinical investigation.
Area of Science:
- Pharmacology
- Hematology
- Thrombosis Research
Background:
- Hirudin, a potent thrombin inhibitor from Hirudo medicinalis, shows therapeutic promise for thrombotic diseases.
- Hemorrhage is a primary risk associated with hirudin therapy.
- Desmopressin (DDAVP) is known for its prohemostatic effects.
Purpose of the Study:
- To investigate if DDAVP infusion can counteract the hemorrhagic effects of continuous hirudin administration.
- To evaluate the efficacy of DDAVP in reducing hirudin-induced bleeding in a rabbit model.
Main Methods:
- Randomized, blinded study in rabbits receiving continuous intravenous hirudin.
- Intermittent intravenous infusion of DDAVP or saline during hirudin therapy.
- Monitoring of bleeding time via ear punctures before, during, and after hirudin exposure.
Main Results:
- Hirudin significantly prolonged primary bleeding time (7-10 fold).
- DDAVP reduced mean bleeding duration from 10.8 to 5.9 minutes (p=0.001).
- DDAVP decreased the proportion of sites with prolonged bleeding (>6 or >20 min) and reduced rebleeding duration.
Conclusions:
- DDAVP effectively attenuates hirudin-induced bleeding in rabbits.
- Findings support further clinical assessment of DDAVP for managing hirudin-related hemorrhage.
- The study utilized two commercial recombinant hirudin preparations with consistent results.